Notably, CYP46A1 offers a promising therapeutic avenue for neurological conditions, as evidenced by alterations in 24S-hydroxycholesterol—a marker closely linked to its function—across disorders such as AD, PD, HD, Niemann–Pick disease type C, and spinocerebellar ataxia [44,49,53,56,137,138]. The gene discussed is CYP46A1; the disease is Huntington disease.